Experience of using prolgolimab in real clinical practice
- Autores: Protsenko S.A1, Imyanitov E.N1,2, Malygin A.Y.1, Yurlov D.O1, Semenova A.I1, Latipova D.K.1, Novik A.V1,2, Teletaeva G.M1, Zinoviev G.V1, Ebert M.A1,2, Artemieva A.S1, Baldueva I.A1
-
Afiliações:
- N.N. Petrov National Medical Research Center of Oncology
- Saint Petersburg State Pediatric Medical University
- Edição: Volume 28, Nº 7 (2021)
- Páginas: 51-55
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313178
- DOI: https://doi.org/10.18565/pharmateca.2021.7.51-55
- ID: 313178
Citar
Texto integral
![Acesso aberto](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Resumo
Palavras-chave
Texto integral
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Sobre autores
S. Protsenko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
E. Imyanitov
N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical UniversitySt. Petersburg, Russia
A. Malygin
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
D. Yurlov
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. Semenova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
D. Latipova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. Novik
N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical UniversitySt. Petersburg, Russia
G. Teletaeva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
G. Zinoviev
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
M. Ebert
N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical UniversitySt. Petersburg, Russia
A. Artemieva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
I. Baldueva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
Bibliografia
- Tjulandin S., Fedyanin M., Semiglazova T., et al. BCD-100 - first Russian PD-1 inhibitor. J Mod Oncol. 2017;19:13-20.
- Tjulandin S., et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer. 2021;149:222-32. doi: 10.1016/j.ejca.2021.02.030.
- Rozeman E.A., et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021; 27(2):256-63. doi: 10.1038/s41591-020- 01211-7
- Blank C.U., Reijers I.L.M., Pennington T., et al. First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol. 2020;38;15S. URL: https://meetinglibrary.asco.org/record/185836/ abstract
- Krishnamoorthy M., Lenehan J.G., Vareki S.M. Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges, JNCI: J Nation Cancer Inst. 2021, djaa216. doi: 10.1093/jnci/djaa216. 7-y
- Huang A.C., et al.Asingledose ofneoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 2019;25(3):454-61. doi: 10.1038/s41591-019-0357-y
Arquivos suplementares
![](/img/style/loading.gif)